Eugenio Catone @CatoneEugenio: "The FDA approved the Wegovy..."

Italy

The FDA approved the Wegovy pill, the first oral GLP-1 for obesity in the US. After months of doubts, this approval feels like a true turning point. The pill delivered 16.6% average weight loss in 64 weeks, with durable results and cardiovascular benefits, outperforming Eli Lilly’s upcoming oral competitor. With no competition for about 90 days, strong patient preference for pills over injections, improved supply readiness, and a low $149 monthly starting price, demand could be massive. Despite the recent rally, Novo still looks undervalued, setting the stage for a powerful comeback in 2026. The stock price is soaring: we can consider it Novo's Christmas gift. $NVO (Novo-Nordisk A/S SPONS ADR) $NOVO-B.CO (Novo Nordisk B A/S) $LLY (Eli Lilly & Co) $USDDKK www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472

Not investment advice. The author may have financial interests in the mentioned instruments.